1 / 1

HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo

HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo. 70. 60. placebo. 30. dalcetrapib. 50. HDL-cholesterol (mg/dL). 20. % change from baseline in non-ABCA1-specific cholesterol efflux. 40. placebo. dalcetrapib. 30. 10. 20. 0. 0. 4. 8.

marisa
Download Presentation

HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HDL-c levels and non-ABCA1-specific cholesterol efflux capacity after CETP-inhibition or placebo 70 60 placebo 30 dalcetrapib 50 HDL-cholesterol (mg/dL) 20 % change from baseline in non-ABCA1-specific cholesterol efflux 40 placebo dalcetrapib 30 10 20 0 0 4 8 12 20 0 4 12 20 week week Ray et al., Eur Heart J 2014

More Related